Eli Lilly's announcement this month that it will pay 3.8 billion dollars for AtaiBeckley, a clinical stage biotech working on psychedelic psychiatric therapies, marks the return of these compounds to the treatment of mental illness rather than only to the culture around it.
The mechanism is what makes it interesting. Conventional antidepressants alter brain chemistry gradually over weeks. The compounds AtaiBeckley has taken through advanced trials aim to rewire neural connections over a small number of doses. That is a different therapeutic shape, and it targets patients who do not respond to existing treatment. The American regulator has granted breakthrough designations to LSD for generalised anxiety disorder, MDMA for post traumatic stress disorder, and psilocybin for treatment resistant depression.
The difficulties are equally structural. These drugs are given in controlled doses alongside psychotherapy, which makes it hard to separate the effect of the compound from the effect of the therapy in a trial. Safety questions around side effects and addiction are unresolved. Dosing strategy is unsettled, with single day administration and redosing both under evaluation. And because these substances have a long history of recreational use, clinical practice will have to distinguish patient motivation in a way it does not for most prescriptions.
For Indian pharmaceutical companies the relevant point is timing rather than novelty. This is a segment that could grow larger than the existing market for mental health drugs, and the domestic industry's strength has always been in manufacturing and formulation once a category is established. Deciding whether to move earlier than that, into trials rather than after them, is the question worth putting on the table now.